Osteoporosis PHCL 442 Hadeel Al-Kofide MS.c. Topics to be covered Definition & epidemiology...
-
Upload
drusilla-roberts -
Category
Documents
-
view
217 -
download
0
Transcript of Osteoporosis PHCL 442 Hadeel Al-Kofide MS.c. Topics to be covered Definition & epidemiology...
![Page 1: Osteoporosis PHCL 442 Hadeel Al-Kofide MS.c. Topics to be covered Definition & epidemiology Pathophysiology Classification Risk factors Diagnosis Management:](https://reader036.fdocuments.us/reader036/viewer/2022062321/56649dc35503460f94ab55d1/html5/thumbnails/1.jpg)
Osteoporosis
PHCL 442
Osteoporosis
PHCL 442
Hadeel Al-Kofide MS.c
![Page 2: Osteoporosis PHCL 442 Hadeel Al-Kofide MS.c. Topics to be covered Definition & epidemiology Pathophysiology Classification Risk factors Diagnosis Management:](https://reader036.fdocuments.us/reader036/viewer/2022062321/56649dc35503460f94ab55d1/html5/thumbnails/2.jpg)
Topics to be coveredTopics to be covered
• Definition & epidemiology
• Pathophysiology
• Classification
• Risk factors
• Diagnosis
• Management:
• Non-Pharmacological & Pharmacological
![Page 3: Osteoporosis PHCL 442 Hadeel Al-Kofide MS.c. Topics to be covered Definition & epidemiology Pathophysiology Classification Risk factors Diagnosis Management:](https://reader036.fdocuments.us/reader036/viewer/2022062321/56649dc35503460f94ab55d1/html5/thumbnails/3.jpg)
DefinitionDefinition
• Osteoporosis is a systemic skeletal disorder characterized by:
low BMD & microarchitectural deterioration of bone tissue,
leading to enhanced bone fragility & a consequent increase in
fracture risk
• The condition is usually painless until a fracture occurs
• It affects 1:2 women & 1:8 men
![Page 4: Osteoporosis PHCL 442 Hadeel Al-Kofide MS.c. Topics to be covered Definition & epidemiology Pathophysiology Classification Risk factors Diagnosis Management:](https://reader036.fdocuments.us/reader036/viewer/2022062321/56649dc35503460f94ab55d1/html5/thumbnails/4.jpg)
PathophysiologyPathophysiology
• Normally there is a balance between osteoblast & osteoclast
activity
• In osteoporosis either one of 2 or both will happen:
Space where some bone has been resorbed (due to osteoclast)
but not yet replaced during the remodeling process (with
osteoblas), this happens by advanced age
Remodeling space is increased (due to osteoclast) in
postmenopausal osteoporosis
![Page 5: Osteoporosis PHCL 442 Hadeel Al-Kofide MS.c. Topics to be covered Definition & epidemiology Pathophysiology Classification Risk factors Diagnosis Management:](https://reader036.fdocuments.us/reader036/viewer/2022062321/56649dc35503460f94ab55d1/html5/thumbnails/5.jpg)
ClassificationClassification
• Primary:
Type I: Postmenopausal osteoporosis, it occurs in women 3-6 years after menopause (due to increase osteoclast resorption activity)
Type II: In both men & women after age 75, female to male ratio 2:1
• Secondary:
Due to drugs, medical problems & other causes it is equal in men & women
![Page 6: Osteoporosis PHCL 442 Hadeel Al-Kofide MS.c. Topics to be covered Definition & epidemiology Pathophysiology Classification Risk factors Diagnosis Management:](https://reader036.fdocuments.us/reader036/viewer/2022062321/56649dc35503460f94ab55d1/html5/thumbnails/6.jpg)
Risk Factors for OsteoporosisRisk Factors for Osteoporosis
• Age – especially after 60 yr
• Female gender
• Small stature
• Caucasian, Asian, Latin American
• Slight body build
• Estrogen depletion (menopause or amenorrhea)
• Family history of osteoporosis
• Lack of exercise
![Page 7: Osteoporosis PHCL 442 Hadeel Al-Kofide MS.c. Topics to be covered Definition & epidemiology Pathophysiology Classification Risk factors Diagnosis Management:](https://reader036.fdocuments.us/reader036/viewer/2022062321/56649dc35503460f94ab55d1/html5/thumbnails/7.jpg)
Risk Factors for OsteoporosisRisk Factors for Osteoporosis
• Cigarette smoking
• Underweight
• Excessive use of alcohol
• Excessive fiber consumption
• Excessive caffeine consumption
• Inadequate lifetime calcium intake
• Poor vitamin D status
![Page 8: Osteoporosis PHCL 442 Hadeel Al-Kofide MS.c. Topics to be covered Definition & epidemiology Pathophysiology Classification Risk factors Diagnosis Management:](https://reader036.fdocuments.us/reader036/viewer/2022062321/56649dc35503460f94ab55d1/html5/thumbnails/8.jpg)
Risk Factors for OsteoporosisRisk Factors for Osteoporosis
Use of certain medications
• Phenytoin, Phenobarbital
• Thyroid hormone
• Corticosteroids
• Methotrexate
• Aluminum-containing antacids
• Heparin
![Page 9: Osteoporosis PHCL 442 Hadeel Al-Kofide MS.c. Topics to be covered Definition & epidemiology Pathophysiology Classification Risk factors Diagnosis Management:](https://reader036.fdocuments.us/reader036/viewer/2022062321/56649dc35503460f94ab55d1/html5/thumbnails/9.jpg)
Risk Factors for OsteoporosisRisk Factors for Osteoporosis
Certain diseases or conditions
• Hyperthyroidism
• Diabetes
• Chronic renal failure
• Chronic diarrhea/malabsorption
• Hyperparathyroidism
• Chronic obstructive lung disease
![Page 10: Osteoporosis PHCL 442 Hadeel Al-Kofide MS.c. Topics to be covered Definition & epidemiology Pathophysiology Classification Risk factors Diagnosis Management:](https://reader036.fdocuments.us/reader036/viewer/2022062321/56649dc35503460f94ab55d1/html5/thumbnails/10.jpg)
DiagnosisDiagnosis
• Radiographic measurement of bone density
• Laboratory biochemical markers
Bone resorption markers (eg., collagen cross-linked N-
telopeptides)
Bone formation markers (eg., bone-specific alkaline
phosphatase)
• Bone biopsy with pathologic assessment: only used under
research setting or with difficult to diagnosis cases
![Page 11: Osteoporosis PHCL 442 Hadeel Al-Kofide MS.c. Topics to be covered Definition & epidemiology Pathophysiology Classification Risk factors Diagnosis Management:](https://reader036.fdocuments.us/reader036/viewer/2022062321/56649dc35503460f94ab55d1/html5/thumbnails/11.jpg)
Bone Mineral DensityBone Mineral Density
Indications:
• In women with strong risk factors
• In those with osteoporosis-related fractures (wrist, spine,
proximal femur, or humerus after mild or moderate trauma)
• For monitoring treatment
![Page 12: Osteoporosis PHCL 442 Hadeel Al-Kofide MS.c. Topics to be covered Definition & epidemiology Pathophysiology Classification Risk factors Diagnosis Management:](https://reader036.fdocuments.us/reader036/viewer/2022062321/56649dc35503460f94ab55d1/html5/thumbnails/12.jpg)
Bone Mineral DensityBone Mineral Density
Techniques:
![Page 13: Osteoporosis PHCL 442 Hadeel Al-Kofide MS.c. Topics to be covered Definition & epidemiology Pathophysiology Classification Risk factors Diagnosis Management:](https://reader036.fdocuments.us/reader036/viewer/2022062321/56649dc35503460f94ab55d1/html5/thumbnails/13.jpg)
Bone Mineral DensityBone Mineral Density
WHO Diagnostic Categories for BMD
Normal BMD not more than 1 SD below the peak bone mass or young adult mean (T-score above -1)
Osteopenia BMD between 1 & 2.5 SD below the young adult mean (T-score between -1 and -2.5)
Osteoporosis BMD 2.5 SD or more below the young adult mean (T-score at or below -2.5)
Severe osteoporosis (established osteoporosis)
BMD 2.5 SD or more below the young adult mean (T-score at or below -2.5) & the presence of one or more fragility fractures
![Page 14: Osteoporosis PHCL 442 Hadeel Al-Kofide MS.c. Topics to be covered Definition & epidemiology Pathophysiology Classification Risk factors Diagnosis Management:](https://reader036.fdocuments.us/reader036/viewer/2022062321/56649dc35503460f94ab55d1/html5/thumbnails/14.jpg)
ManagementManagement
![Page 15: Osteoporosis PHCL 442 Hadeel Al-Kofide MS.c. Topics to be covered Definition & epidemiology Pathophysiology Classification Risk factors Diagnosis Management:](https://reader036.fdocuments.us/reader036/viewer/2022062321/56649dc35503460f94ab55d1/html5/thumbnails/15.jpg)
Management & PreventionManagement & Prevention
• Keep in mind you have two prevent osteoporosis in 2 settings:
Premenopausal women
Postmenopausal women
![Page 16: Osteoporosis PHCL 442 Hadeel Al-Kofide MS.c. Topics to be covered Definition & epidemiology Pathophysiology Classification Risk factors Diagnosis Management:](https://reader036.fdocuments.us/reader036/viewer/2022062321/56649dc35503460f94ab55d1/html5/thumbnails/16.jpg)
Non-PharmacologicalNon-Pharmacological
• Appropriate levels of exercise should be recommended
• Smoking & alcohol abuse should be discouraged
• Physiotherapy & pain relief are important in managing
fractures
![Page 17: Osteoporosis PHCL 442 Hadeel Al-Kofide MS.c. Topics to be covered Definition & epidemiology Pathophysiology Classification Risk factors Diagnosis Management:](https://reader036.fdocuments.us/reader036/viewer/2022062321/56649dc35503460f94ab55d1/html5/thumbnails/17.jpg)
PharmacologicalPharmacological
• Calcium & vitamin D
• Hormone replacement therapy
• Raloxifene
• Bisphosphonates
• Calcitonin
• Parathyroid hormone peptides
• Strontium ranelate
![Page 18: Osteoporosis PHCL 442 Hadeel Al-Kofide MS.c. Topics to be covered Definition & epidemiology Pathophysiology Classification Risk factors Diagnosis Management:](https://reader036.fdocuments.us/reader036/viewer/2022062321/56649dc35503460f94ab55d1/html5/thumbnails/18.jpg)
Calcium & Vitamin DCalcium & Vitamin D
• All patients at risk for osteoporosis (for prevention) & patients
with osteoporosis (for treatment) should be on adequate Ca &
vitamin D supplements
• Calcium dose: 1200 mg elemental Ca
• Vitamin D dose: 400 IU/day if age more than 70 years 600
IU/day
![Page 19: Osteoporosis PHCL 442 Hadeel Al-Kofide MS.c. Topics to be covered Definition & epidemiology Pathophysiology Classification Risk factors Diagnosis Management:](https://reader036.fdocuments.us/reader036/viewer/2022062321/56649dc35503460f94ab55d1/html5/thumbnails/19.jpg)
Calcium & Vitamin DCalcium & Vitamin D
• Calcium carbonate: highest amount of calcium per tablet, but
may cause intestinal gas &/or constipation
• Calcium citrate: less calcium per tablet, but better absorbed
than carbonate; no known side effects
• Calcium phosphate: most diets already high in phosphorous;
better to avoid this form
• Calcium gluconate: requires many tablets to obtain sufficient
calcium
![Page 20: Osteoporosis PHCL 442 Hadeel Al-Kofide MS.c. Topics to be covered Definition & epidemiology Pathophysiology Classification Risk factors Diagnosis Management:](https://reader036.fdocuments.us/reader036/viewer/2022062321/56649dc35503460f94ab55d1/html5/thumbnails/20.jpg)
Vitamin D inadequacy worldwide
Vitamin D inadequacy defined as serum 25(OH)D <30 ng/ml
1285 community-dwelling women with osteoporosis from 18 countries to evaluate serum 25(OH)D distribution.
Lim S-K et al, 2005
Pre
vale
nce
(%
)
0
10
30
40
60
80
90
LatinAmerica
51%
63%
AsiaAll
59%
Australia
59%
Europe
52%
Regions
N=1285 81%
MiddleEast
50
70
20
![Page 21: Osteoporosis PHCL 442 Hadeel Al-Kofide MS.c. Topics to be covered Definition & epidemiology Pathophysiology Classification Risk factors Diagnosis Management:](https://reader036.fdocuments.us/reader036/viewer/2022062321/56649dc35503460f94ab55d1/html5/thumbnails/21.jpg)
Hormone Replacement TherapyHormone Replacement Therapy
• In the past was considered as 1st line treatment
• It is an appropriate option in younger postmenopausal women
at high risk of fracture, particularly those with vasomotor
symptoms
• Generally a second line treatment option because risk-benefit
balance is unfavorable in older women
![Page 22: Osteoporosis PHCL 442 Hadeel Al-Kofide MS.c. Topics to be covered Definition & epidemiology Pathophysiology Classification Risk factors Diagnosis Management:](https://reader036.fdocuments.us/reader036/viewer/2022062321/56649dc35503460f94ab55d1/html5/thumbnails/22.jpg)
RaloxifeneRaloxifene
Mechanism of action:
• Selective estrogen receptor modulator (SERM)
• Mixed estrogen receptor agonist/antagonist
• Acts as an agonist in the bone, reducing turnover by inhibiting
osteoclast recruitment & activity
• Acts as an antagonist in the breast & uterus
![Page 23: Osteoporosis PHCL 442 Hadeel Al-Kofide MS.c. Topics to be covered Definition & epidemiology Pathophysiology Classification Risk factors Diagnosis Management:](https://reader036.fdocuments.us/reader036/viewer/2022062321/56649dc35503460f94ab55d1/html5/thumbnails/23.jpg)
RaloxifeneRaloxifene
Role in Therapy:
• Second line agent for the treatment of postmenopausal
osteoporosis
Advantage:
• Favorable changes in lipid profile
• Decreases the risk for CV events and breast cancer
![Page 24: Osteoporosis PHCL 442 Hadeel Al-Kofide MS.c. Topics to be covered Definition & epidemiology Pathophysiology Classification Risk factors Diagnosis Management:](https://reader036.fdocuments.us/reader036/viewer/2022062321/56649dc35503460f94ab55d1/html5/thumbnails/24.jpg)
RaloxifeneRaloxifene
Dose:
• 60 mg/day
Adverse effects:
• Hot flushes, & leg cramps
• Increase in the relative risk of venous thromboembolism
![Page 25: Osteoporosis PHCL 442 Hadeel Al-Kofide MS.c. Topics to be covered Definition & epidemiology Pathophysiology Classification Risk factors Diagnosis Management:](https://reader036.fdocuments.us/reader036/viewer/2022062321/56649dc35503460f94ab55d1/html5/thumbnails/25.jpg)
BisphosphonatesBisphosphonates
Mechanism of action:
• Deposited in bone at the site of mineralization; apparently
causing the death of osteoclasts which results in decreased
bone resorption
They have very long half life 1-2 years
Less than 10% absorbed
![Page 26: Osteoporosis PHCL 442 Hadeel Al-Kofide MS.c. Topics to be covered Definition & epidemiology Pathophysiology Classification Risk factors Diagnosis Management:](https://reader036.fdocuments.us/reader036/viewer/2022062321/56649dc35503460f94ab55d1/html5/thumbnails/26.jpg)
BisphosphonatesBisphosphonates
• Alendronate & risedronate have been shown to reduce
vertebral & non-vertebral fractures, including hip fractures
• They are considered first line options for treating
postmenopausal osteoporosis
![Page 27: Osteoporosis PHCL 442 Hadeel Al-Kofide MS.c. Topics to be covered Definition & epidemiology Pathophysiology Classification Risk factors Diagnosis Management:](https://reader036.fdocuments.us/reader036/viewer/2022062321/56649dc35503460f94ab55d1/html5/thumbnails/27.jpg)
BisphosphonatesBisphosphonates
Dose:
Alendronate Oral 70 mg 1/w, or
5 mg or 10 mg OD
Etidronate Oral 400 mg OD for 2 w every 3 mo
Ibandronate Oral
IV
150 mg 1/mo
3 mg 1/3 mo
Risedronate Oral 35 mg 1/w, or
5 mg OD
Most common regimen used
The only one with IV form
![Page 28: Osteoporosis PHCL 442 Hadeel Al-Kofide MS.c. Topics to be covered Definition & epidemiology Pathophysiology Classification Risk factors Diagnosis Management:](https://reader036.fdocuments.us/reader036/viewer/2022062321/56649dc35503460f94ab55d1/html5/thumbnails/28.jpg)
BisphosphonatesBisphosphonates
Adverse effects:
• Acid regurgitation, dyspepsia, abdominal distention, gastritis,
nausea & dysphagia
• Esophageal ulceration & strictures
• Musculoskeletal pain, headache & rash
![Page 29: Osteoporosis PHCL 442 Hadeel Al-Kofide MS.c. Topics to be covered Definition & epidemiology Pathophysiology Classification Risk factors Diagnosis Management:](https://reader036.fdocuments.us/reader036/viewer/2022062321/56649dc35503460f94ab55d1/html5/thumbnails/29.jpg)
BisphosphonatesBisphosphonates
Contraindications:
• Not given if CrCl less than 35 ml/min
• If hypocalcaemia exists it should be corrected before starting
therapy
• Caution in patients with upper GI problem (esophagus)
![Page 30: Osteoporosis PHCL 442 Hadeel Al-Kofide MS.c. Topics to be covered Definition & epidemiology Pathophysiology Classification Risk factors Diagnosis Management:](https://reader036.fdocuments.us/reader036/viewer/2022062321/56649dc35503460f94ab55d1/html5/thumbnails/30.jpg)
BisphosphonatesBisphosphonates
Precautions:
• Oral bisphosphonates must be taken fasting, with a full glass
of water
• The individual must be upright & stay sitting or standing
without taking food or drink for the next 30-60 minutes
• This is done to prevent esophageal ulceration
![Page 31: Osteoporosis PHCL 442 Hadeel Al-Kofide MS.c. Topics to be covered Definition & epidemiology Pathophysiology Classification Risk factors Diagnosis Management:](https://reader036.fdocuments.us/reader036/viewer/2022062321/56649dc35503460f94ab55d1/html5/thumbnails/31.jpg)
CalcitoninCalcitonin
Mechanism of action:
• Inhibits osteoclast formation & attachment
• Analgesic effect?
Dose:
• 200 IU/day by nasal spray
• 100 IU/day IM
![Page 32: Osteoporosis PHCL 442 Hadeel Al-Kofide MS.c. Topics to be covered Definition & epidemiology Pathophysiology Classification Risk factors Diagnosis Management:](https://reader036.fdocuments.us/reader036/viewer/2022062321/56649dc35503460f94ab55d1/html5/thumbnails/32.jpg)
CalcitoninCalcitonin
Adverse effects:
• Rhinitis & epistaxis (from nasal form)
• Arthralgia, headache & back pain
• Flushing, nausea, vomiting & local irritation (IM)
![Page 33: Osteoporosis PHCL 442 Hadeel Al-Kofide MS.c. Topics to be covered Definition & epidemiology Pathophysiology Classification Risk factors Diagnosis Management:](https://reader036.fdocuments.us/reader036/viewer/2022062321/56649dc35503460f94ab55d1/html5/thumbnails/33.jpg)
CalcitoninCalcitonin
Precautions:
• Nasal form should be refrigerated until it is open for use
• After opening it is only stable for 30 days at room temperature
Role in Therapy:
• Not used as first line treatment
• Mainly used in patients with back pain & acute vertebral fracture
![Page 34: Osteoporosis PHCL 442 Hadeel Al-Kofide MS.c. Topics to be covered Definition & epidemiology Pathophysiology Classification Risk factors Diagnosis Management:](https://reader036.fdocuments.us/reader036/viewer/2022062321/56649dc35503460f94ab55d1/html5/thumbnails/34.jpg)
Parathyroid HormoneParathyroid Hormone
Mechanism of action:
• Produced normally by PT gland, helps control calcium
exchange between the bones & the blood stream
• Low dose synthetic human PTH causes anabolic response,
increasing the number and action of osteoblasts
![Page 35: Osteoporosis PHCL 442 Hadeel Al-Kofide MS.c. Topics to be covered Definition & epidemiology Pathophysiology Classification Risk factors Diagnosis Management:](https://reader036.fdocuments.us/reader036/viewer/2022062321/56649dc35503460f94ab55d1/html5/thumbnails/35.jpg)
Parathyroid HormoneParathyroid Hormone
Side effects:
• Asymptomatic mild hypercalcemia
• Increase risk of osteosarcoma
Dose:
• Teriparatide (rPTH): 20 mcg/d SC for upto 24 months
![Page 36: Osteoporosis PHCL 442 Hadeel Al-Kofide MS.c. Topics to be covered Definition & epidemiology Pathophysiology Classification Risk factors Diagnosis Management:](https://reader036.fdocuments.us/reader036/viewer/2022062321/56649dc35503460f94ab55d1/html5/thumbnails/36.jpg)
Parathyroid HormoneParathyroid Hormone
Contraindications:
• Children, adolescents & patients with paget’s disease because of
increased risk of osteosarcoma
• Hypercalcemia
Role in Therapy:
• Postmenopausal women & men with osteoporosis who are at
high risk for fracture, such as individuals with prior osteoporotic
fractures (mainly as second line agent)
![Page 37: Osteoporosis PHCL 442 Hadeel Al-Kofide MS.c. Topics to be covered Definition & epidemiology Pathophysiology Classification Risk factors Diagnosis Management:](https://reader036.fdocuments.us/reader036/viewer/2022062321/56649dc35503460f94ab55d1/html5/thumbnails/37.jpg)
Strontium RanelateStrontium Ranelate
Mechanism of action:
• It has a dual mode of action, both increasing bone formation &
decreasing bone resorption
• It has been shown to enhance osteoblastic cell replication &
increase collagen synthesis while it decreases bone-resorbing
activity of mature osteoclasts
![Page 38: Osteoporosis PHCL 442 Hadeel Al-Kofide MS.c. Topics to be covered Definition & epidemiology Pathophysiology Classification Risk factors Diagnosis Management:](https://reader036.fdocuments.us/reader036/viewer/2022062321/56649dc35503460f94ab55d1/html5/thumbnails/38.jpg)
Strontium RanelateStrontium Ranelate
Adverse effects:
• Diarrhoea, nausea, headache, dermatitis & eczema
• Rare: DVT
Contraindications:
• Not recommended in patients with a CrCl below 30 ml/min
Dose:
• 2 g sachet once daily 2 hours after food, must taken as
suspension in water & drink immediately
![Page 39: Osteoporosis PHCL 442 Hadeel Al-Kofide MS.c. Topics to be covered Definition & epidemiology Pathophysiology Classification Risk factors Diagnosis Management:](https://reader036.fdocuments.us/reader036/viewer/2022062321/56649dc35503460f94ab55d1/html5/thumbnails/39.jpg)
Strontium RanelateStrontium Ranelate
Role in Therapy:
• Postmenopausal women & men with osteoporosis who are at
high risk for fracture, such as individuals with prior
osteoporotic fractures (mainly as second line agent)
![Page 40: Osteoporosis PHCL 442 Hadeel Al-Kofide MS.c. Topics to be covered Definition & epidemiology Pathophysiology Classification Risk factors Diagnosis Management:](https://reader036.fdocuments.us/reader036/viewer/2022062321/56649dc35503460f94ab55d1/html5/thumbnails/40.jpg)
Which Dug for Which Patient??Which Dug for Which Patient??
![Page 41: Osteoporosis PHCL 442 Hadeel Al-Kofide MS.c. Topics to be covered Definition & epidemiology Pathophysiology Classification Risk factors Diagnosis Management:](https://reader036.fdocuments.us/reader036/viewer/2022062321/56649dc35503460f94ab55d1/html5/thumbnails/41.jpg)
Which drug for which patient?
Agent Rx PM OP to reduce risk of
Steroid induced
OP
OP in men
Vertebral fractures
Hip fractures
Alendronate Risedronate
Etidronate
Raloxifene
Strontium ranelate
Teriparatide
LOOK AT THE ATTACHED GUIDELINE
![Page 42: Osteoporosis PHCL 442 Hadeel Al-Kofide MS.c. Topics to be covered Definition & epidemiology Pathophysiology Classification Risk factors Diagnosis Management:](https://reader036.fdocuments.us/reader036/viewer/2022062321/56649dc35503460f94ab55d1/html5/thumbnails/42.jpg)
Thank youThank you